Date: 2013-02-25
Type of information:
Compound: new antibiotics
Company: Xellia Pharmaceuticals (Norway) SINTEF Materials and Chemistry (Denmark) the Statens Serum Institut (Denmark)
Therapeutic area: Infectious diseases
Type agreement:
Action mechanism:
Disease: multi-drug resistant (MDR), Gram-negative bacteria infections
Details: * On February 25, 2013, Xellia Pharmaceuticals, a fully integrated specialty pharmaceutical company focusing on the global anti-infective market, has announced that it is developing new antibiotics effective against multi-drug resistant (MDR), Gram-negative bacteria. This four year development project at Xellia is a collaboration with SINTEF Materials and Chemistry (Trondheim) and the Statens Serum Institut (Copenhagen).
The project is being supported by a $3 million grant from the Research Council of Norway (NFR). The project also includes contributions from laboratories across Europe. Xellia is aiming to develop new antibiotics that target Gram-negative bacterial infections, caused by, for example Pseudomonas, Klebsiella, Acinetobacter and Enterobacterspecies.
Financial terms:
Latest news:
